CorMedix Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Financial Performance - CorMedix Inc. is set to release its fourth-quarter financial results on March 25, with analysts expecting earnings of 14 cents per share, a significant improvement from a loss of 26 cents per share in the same period last year [1] - The company projects quarterly revenue of $28.34 million [1] Business Developments - On January 21, CorMedix announced its engagement with WSI PBG to promote DefenCath® to healthcare providers in facilities operated by the Department of Veterans Affairs and other federal facilities [2] - Following this announcement, CorMedix shares increased by 0.5%, closing at $10.91 [2] Analyst Ratings - Needham analyst Serge Belanger maintained a Buy rating and raised the price target from $10 to $18, with an accuracy rate of 69% [4] - Truist Securities analyst Joon Lee also maintained a Buy rating, increasing the price target from $12 to $17, with an accuracy rate of 78% [4]